Immunotherapy against EBV-lymphoma in recipients of HSCT

References

• Rickinson AB, Kieff E. Epstein–Barr Virus. In: Fields Virology. Knipe DM, Howley PM (Eds). Lippincott Williams & Williams, PA, USA 2575–2628 (2001).
   Google Scholar
• Cohen JI. Epstein–Barr virus infection. N. Engl. J. Med.343, 481–492 (2000).
   PubMed Web of Science ®Google Scholar
• Williams H, Crawford DH. Epstein–Barr virus: the impact of scientific advances on clinical practice. Blood107, 862–869 (2006).
   PubMed Web of Science ®Google Scholar
• Deyrup AT. Epstein–Barr virus-associated epithelial and mesenchymal neoplasms. Hum. Pathol.39, 473–483 (2008).
   PubMed Web of Science ®Google Scholar
• Gottschalk S, Rooney CM, Heslop HE. Post-transplant lymphoproliferative disorders. Annu. Rev. Med.56, 29–44 (2005).
   PubMed Web of Science ®Google Scholar
• Thorley-Lawson DA, Gross A. Persistence of the Epstein–Barr virus and the origins of associated lymphomas. N. Engl. J. Med.350, 1328–1337 (2004).
   PubMed Web of Science ®Google Scholar
• Shapiro RS, McClain K, Frizzera G et al. Epstein–Barr virus associated B-cell lymphoproliferative disorders following bone marrow transplantation. Blood171, 1234–1243 (1988).
   Google Scholar
• Zutter MM, Martin PJ, Sale GE et al. Epstein–Barr virus lymphoproliferation after bone marrow transplantation. Blood72, 520–529 (1988).
   PubMed Web of Science ®Google Scholar
• Starzl TE, Naleskin MA, Porter KA et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet.1, 583–587 (1984).
   PubMed Web of Science ®Google Scholar
• Papadopoulos EB, Ladanyi M, Emanuel D et al. Infusions of donor leukocytes as treatment of Epstein–Barr virus associated lymphoproliferative disorders complicating allogeneic marrow transplantation. N. Engl. J. Med.330, 1185–1191 (1994).
   PubMed Web of Science ®Google Scholar
• Curtis RE, Travis LB, Rowlings PA et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood94, 2208–2216 (1999).
   PubMed Web of Science ®Google Scholar
• Knight JS, Tsodikov A, Cibrik DM, Ross CW, Kaminski MS, Blayney DW. Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center. J. Clin. Oncol.27, 3354–3362 (2009).
   PubMed Web of Science ®Google Scholar
• Comoli P, Rooney CM. Treatment of Epstein–Barr virus infections. In: Epstein–Barr Virus. Jenson HB, Tselis A (Eds). Taylor & Francis, NY, USA 351–372 (2006).
   Google Scholar
• Rooney CM, Smith CA, Ng CY et al. Use of gene-modified virus-specific T lymphocytes to control Epstein–Barr-virus-related lymphoproliferation. Lancet345, 9–12 (1995).
   PubMed Web of Science ®Google Scholar
• Rooney CM, Smith CA, Ng CYC et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein–Barr virus-induced lymphoma in allogeneic transplant recipients. Blood92, 1549–1555 (1998).
   PubMed Web of Science ®Google Scholar
• Haque T, Wilkie GM, Taylor C et al. Treatment of Epstein–Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet360, 436–442 (2002).
   PubMed Web of Science ®Google Scholar
• Comoli P, Basso S, Zecca M et al. Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation. Am. J. Transplant7, 1648–1655 (2007).
   PubMed Web of Science ®Google Scholar
• Khanna R, Bell S, Sherritt M et al. Activation and adoptive transfer of Epstein–Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc. Natl. Acad. Sci. USA96, 10391–10396 (1999).
   PubMed Web of Science ®Google Scholar
• Comoli P, Labirio M, Basso S et al. Infusion of autologous Epstein–Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood99, 2592–2598 (2002).
   PubMed Web of Science ®Google Scholar
• Bollard CM, Aguilar L, Straathof KC et al. Cytotoxic T lymphocyte therapy for Epstein–Barr virus Hodgkin’s disease. J. Exp. Med.200, 1623–1633 (2004).
   PubMed Web of Science ®Google Scholar
• Comoli P, Pedrazzoli P, Maccario R et al. Cell therapy of stage IV nasopharyngeal carcinoma with autologous EBV-targeted cytotoxic T-lymphocytes. J. Clin. Oncol.23, 8942–8949 (2005).
   PubMed Web of Science ®Google Scholar
• Ressing ME, Horst D, Griffin BD et al. Epstein–Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products. Semin. Cancer Biol.18, 397–408 (2008).
   PubMed Web of Science ®Google Scholar
• Rickinson AB, Moss DJ. Human cytotoxic T lymphocyte responses to Epstein–Barr virus infection. Annu. Rev. Immunol.15, 405–431 (1997).
   PubMed Web of Science ®Google Scholar
• Capello D, Gaidano G. Post-transplant lymphoproliferative disorders: role of viral infection, genetic lesions, and antigen stimulation in the pathogenesis of the disease. Medit. J. Hemat. Infect. Dis.1, e2009018 (2009).
   Google Scholar
• Landgren O, Gilbert ES, Rizzo JD et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood113, 4992–5001 (2009).
   PubMed Web of Science ®Google Scholar
• Cavazzana-Calvo M, Bensoussan D, Jabado N et al. Prevention of EBV induced B-lymphoproliferative disorder by ex vivo marrow B-cell depletion in HLA-phenoidentical or non-identical T-depleted bone marrow transplantation. Br. J. Haematol.103, 543–551 (1998).
   PubMed Web of Science ®Google Scholar
• Gross TG, Steinbuch M, DeFor T et al. B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome. Bone Marrow Transplant.23, 251–258 (1999).
   PubMed Web of Science ®Google Scholar
• Swinnen LJ. Overview of posttransplant B-cell lymphoproliferative disorders. Semin. Oncol.26, 21–25 (1999).
   PubMed Web of Science ®Google Scholar
• Savoie A, Perpete C, Carpentier L, Joncas J, Alfieri C. Direct correlation between the load of Epstein–Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease. Blood83, 2715–2722 (1994).
   PubMed Web of Science ®Google Scholar
• Rooney CM, Loftin SK, Holladay MS, Brenner MK, Krance RA, Heslop HE. Early identification of Epstein–Barr virus-associated posttransplantation lymphoproliferative disease. Br. J. Haematol.89, 98–103 (1995).
   PubMed Web of Science ®Google Scholar
• Rowe DT, Webber S, Schauer EM et al. Epstein–Barr virus load monitoring: its role in the prevention and management of post-transplant lymphoproliferative disease. Transpl. Infect. Dis.3, 79–87 (2001)
   PubMedGoogle Scholar
• Baldanti F, Gatti M, Furione M et al. Kinetics of Epstein–Barr virus DNA load in different blood compartments of pediatric recipients of T-cell depleted HLA-haploidentical stem cell transplantation. J. Clin. Microbiol.46, 3672–3677 (2008).
   PubMed Web of Science ®Google Scholar
• Yang J, Tao Q, Flinn IW et al. Characterization of Epstein–Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response. Blood96, 4055–4063 (2000).
   PubMed Web of Science ®Google Scholar
• Oertel SH, Riess H. Antiviral treatment of Epstein–Barr virus associated lymphoproliferations. Recent Results Cancer Res.159, 89–95 (2002).
   PubMedGoogle Scholar
• Perrine SP, Hermine O, Small T et al. A Phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein–Barr virus-associated lymphoid malignancies. Blood109, 2571–2578 (2007).
   PubMed Web of Science ®Google Scholar
• Slobod K, Taylor GH, Sandlund JT et al. Epstein–Barr virus-targeted therapy for AIDS-related primary lymphoma of the central nervous system. Lancet356, 1493–1494 (2000).
   PubMed Web of Science ®Google Scholar
• Heslop HE. How I treat EBV lymphoproliferation. Blood114, 4002–4008 (2009).
   PubMed Web of Science ®Google Scholar
• Gross TG, Steinbuch M, DeFor T et al. B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome. Bone Marrow Transplant.23, 251–258 (1999).
   PubMed Web of Science ®Google Scholar
• Knight JS, Tsodikov A, Cibrik DM, Ross CW, Kaminski MS, Blayney DW. Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center. J. Clin. Oncol.27(20), 3354–3362 (2009).
   PubMed Web of Science ®Google Scholar
• Evens AM, David KA, Helenowski I et al. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J. Clin. Oncol.28(6), 1038–1046 (2010).
   PubMed Web of Science ®Google Scholar
• Gross TG, Bucuvalas JC, Park JR et al. Low-dose chemotherapy for Epstein–Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation. J. Clin. Oncol.23, 6481–6488 (2005).
   PubMed Web of Science ®Google Scholar
• Fischer A, Blanche S, LeBidois J et al. Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N. Engl. J. Med.324, 1451–1456 (1991).
   PubMed Web of Science ®Google Scholar
• Faye A, Van Den Abeele T, Peuchmaur M, Matheu-Boue A, Vilmer E. Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disorders. Lancet352, 1285 (1998).
   PubMed Web of Science ®Google Scholar
• Kuehnle I, Huls MH, Liu Z et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein–Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood95, 1502–1505 (2000).
   PubMed Web of Science ®Google Scholar
• Choquet S, Leblond V, Herbrecht R et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood107, 3053–3057 (2006).
   PubMed Web of Science ®Google Scholar
• van Esser JWJ, Niesters HGM, van der Holt B et al. Prevention of Epstein–Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high risk patients after allogeneic stem cell transplantation. Blood99, 4364–4369 (2002).
   PubMed Web of Science ®Google Scholar
• Styczynski J, Einsele H, Gil L, Ljungman P. Outcome of treatment of Epstein–Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases. Transpl. Infect. Dis.11, 383–392 (2009).
   PubMed Web of Science ®Google Scholar
• Blaes AH, Cao Q, Wagner JE et al. Monitoring and preemptive rituximab therapy for Epstein–Barr virus reactivation after antithymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantation. Biol. Blood Marrow Transplant.16, 287–291 (2010).
   PubMed Web of Science ®Google Scholar
• Savoldo B, Rooney CM, Quiros-Tejeira RE et al. Cellular immunity to Epstein–Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease. Am. J. Transplant.5, 566–572 (2005).
   PubMed Web of Science ®Google Scholar
• Hale G, Waldmann H, for CAMPATH users. Risks of developing Epstein–Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. Blood91, 3079–3083 (1998).
   PubMed Web of Science ®Google Scholar
• Savani BN, Pohlmann PR, Jagasia M et al. Does peritransplantation use of rituximab reduce the risk of EBV reactivation and PTLPD? Blood113, 6263–6264 (2009).
   PubMed Web of Science ®Google Scholar
• Lucas KG, Burton RL, Zimmerman SE et al. Semiquantitative Epstein–Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation. Blood91, 3654–3661 (1998).
   PubMed Web of Science ®Google Scholar
• Bonini C, Ferrari G, Verzeletti S et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft versus leukemia. Science276, 1719–1724 (1997).
   PubMed Web of Science ®Google Scholar
• Traversari C, Marktel S, Magnani Z et al. The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies. Blood109, 4708–4715 (2007).
   PubMed Web of Science ®Google Scholar
• Sauce D, Bodinier M, Garin M et al. Retrovirus-mediated gene transfer in primary T lymphocytes impairs their anti-Epstein–Barr virus potential through both culture-dependent and selection process-dependent mechanisms. Blood99, 1165–1176 (2002).
   PubMed Web of Science ®Google Scholar
• Gustafsson A, Levitsky V, Zou JZ et al. Epstein–Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood95, 807–814 (2000).
   PubMed Web of Science ®Google Scholar
• Wagner HJ, Cheng YC, Huls MH et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood103, 3979–3981 (2004).
   PubMed Web of Science ®Google Scholar
• Heslop HE, Ng CYC, Li C et al. Long-term restoration of immunity against Epstein–Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat. Med.2, 551–555 (1996).
   PubMed Web of Science ®Google Scholar
• Leen AM, Myers GD, Sili U et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat. Med.12, 1160–1166 (2006).
   PubMed Web of Science ®Google Scholar
• Heslop HE, Slobod KS, Pule MA et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood115, 925–935 (2010).
   PubMed Web of Science ®Google Scholar
• Wilkie GM, Taylor C, Jones MM et al. Establishment and characterization of a bank of cytotoxic T lymphocytes for immunotherapy of Epstein–Barr virus-associated diseases. J. Immunother.27, 309–316 (2004).
   PubMed Web of Science ®Google Scholar
• Haque T, Wilkie GM, Jones MM et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood110, 1123–1131 (2007).
   PubMed Web of Science ®Google Scholar
• Cobbold M, Khan N, Pourgheysari B et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J. Exp. Med.202, 379–386 (2005).
   PubMed Web of Science ®Google Scholar
• Rauser G, Einsele H, Sinzer C et al. Rapid generation of combined CMV-specific CD4+ and CD8+ T-cell lines for adoptive transfer into recipients of allogeneic stem cell transplantation. Blood103, 3565–3572 (2004).
   PubMed Web of Science ®Google Scholar
• Adhikary D, Behrends U, Boerschmann H et al. Immunodominance of lytic cycle antigens in Epstein–Barr virus-specific CD4+ T cell preparations for therapy. PLoS ONE2, e583 (2007).
   PubMed Web of Science ®Google Scholar
• Sun Q, Pollok KE, Burton RL et al. Simultaneous ex vivo expansion of cytomegalovirus and Epstein–Barr virus-specific cytotoxic T lymphocytes using B-lymphoblastoid cell lines expressing cytomegalovirus pp65. Blood94, 3242–3250 (1999).
   PubMed Web of Science ®Google Scholar
• Moosmann A, Bigalke I, Tischer J et al. Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. Blood115, 2960–2970 (2010).
   PubMed Web of Science ®Google Scholar
• Gerdemann U, Christin AS, Vera JF et al. Nucleofection of DCs to generate multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host. Mol. Ther.17, 1616–1625 (2009).
   PubMed Web of Science ®Google Scholar
• Popescu I, Macedo C, Zeevi A et al.Ex vivo priming of naïve T cells into EBV-specific Th1/Tc1 effector cells by mature autologous DC loaded with apoptotic/necrotic LCL. Am. J. Transplant3, 1369–1377 (2003).
   PubMed Web of Science ®Google Scholar
• Savoldo B, Cubbage ML, Durett AG et al. Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals. J. Immunol.168, 909–918 (2002).
   PubMed Web of Science ®Google Scholar
• Comoli P, Ginevri F, Maccario R et al. Successful in vitro priming of EBV-specific CD8+ T cells endowed with strong cytotoxic function from T cells of EBV-seronegative children. Am. J. Transplant6, 2169–2176 (2006).
   PubMed Web of Science ®Google Scholar
• Faraci M, Lanino E, Micalizzi C et al. Unrelated hematopoietic stem cell transplantation for Cernunnos-XLF deficiency. Pediatr. Transplant13, 785–789 (2008).
   PubMed Web of Science ®Google Scholar
• Comoli P. Arming CTLs against immunosuppressors. Blood114, 4759–4760 (2009).
   PubMed Web of Science ®Google Scholar
• Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv. Immunol.90, 51–81 (2006).
   PubMed Web of Science ®Google Scholar
• De Angelis B, Dotti G, Quintarelli C et al. Generation of Epstein–Barr-virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). Blood114, 4784–4791 (2009).
   PubMed Web of Science ®Google Scholar
• Brewin J, Mancao C, Straathof K et al. Generation of EBV-specific cytotoxic T-cells that are resistant to calcineurin inhibitors for the treatment of post-transplant lymphoproliferative disease. Blood114, 4792–4803 (2009).
   PubMed Web of Science ®Google Scholar
• Bollard CM, Rossig C, Calonge MJ et al. Adapting a transforming growth factor β-related tumor protection strategy to enhance antitumor immunity. Blood99, 3179–3187 (2002).
   PubMed Web of Science ®Google Scholar
• Savoldo B, Rooney CM, Di Stasi A et al. Epstein Barr virus–specific cytotoxic T lymphocytes expressing the anti-CD30 artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood110, 2620–2630 (2007).
   PubMed Web of Science ®Google Scholar